Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.

Krug LM, Heelan RT, Kris MG, Venkatraman E, Sirotnak FM.

J Thorac Oncol. 2007 Apr;2(4):317-20.

2.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.

J Clin Oncol. 2003 Jul 15;21(14):2636-44.

PMID:
12860938
3.

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.

Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK; Pemetrexed expanded access program investigators.

J Thorac Oncol. 2006 Jul;1(6):506-12. Erratum in: J Thorac Oncol. 2006 Sep;1(7):621.

4.

Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.

van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G.

Lancet Oncol. 2017 Oct;18(10):1386-1396. doi: 10.1016/S1470-2045(17)30621-6. Epub 2017 Sep 1.

PMID:
28870611
5.

Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results.

Schouwink H, Rutgers ET, van der Sijp J, Oppelaar H, van Zandwijk N, van Veen R, Burgers S, Stewart FA, Zoetmulder F, Baas P.

Chest. 2001 Oct;120(4):1167-74.

PMID:
11591556
6.

Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).

Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M.

Ann Oncol. 2008 Feb;19(2):370-3. Epub 2007 Dec 20.

PMID:
18156144
7.

Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.

Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DM.

J Clin Oncol. 2005 May 20;23(15):3495-501.

PMID:
15908659
8.

Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.

Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ.

Cancer. 2004 Aug 1;101(3):587-95.

9.

A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.

Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PL, Pavlakis N, Boyer M, Stockler MR.

Lung Cancer. 2013 Sep;81(3):422-7. doi: 10.1016/j.lungcan.2013.05.006. Epub 2013 Jun 17.

PMID:
23787063
10.

Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.

Scagliotti GV, Shin DM, Kindler HL, Vasconcelles MJ, Keppler U, Manegold C, Burris H, Gatzemeier U, Blatter J, Symanowski JT, Rusthoven JJ.

J Clin Oncol. 2003 Apr 15;21(8):1556-61.

PMID:
12697881
11.

A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.

Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U, Vrankar M.

Anticancer Drugs. 2012 Feb;23(2):230-8. doi: 10.1097/CAD.0b013e32834d7a1c.

PMID:
22027538
12.

Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.

Astoul P, Picat-Joossen D, Viallat JR, Boutin C.

Cancer. 1998 Nov 15;83(10):2099-104.

PMID:
9827714
13.

Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.

Guadagni S, Clementi M, Valenti M, Fiorentini G, Cantore M, Kanavos E, Amicucci G.

In Vivo. 2006 Nov-Dec;20(6A):715-8.

14.

Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.

Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini E, Ardizzoni A, Fumagalli L, Valsuani G, Botta M.

Lung Cancer. 2001 Feb-Mar;31(2-3):303-10.

PMID:
11165411
15.
16.

A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.

Kataoka Y, Yamamoto Y, Otsuki T, Shinomiya M, Terada T, Fukuma S, Yamazaki S, Hirabayashi M, Nakano T, Fukuhara S.

Jpn J Clin Oncol. 2015 Jun;45(6):562-8. doi: 10.1093/jjco/hyv039. Epub 2015 Apr 2.

17.

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M.

Lancet Oncol. 2013 Oct;14(11):1104-1111. doi: 10.1016/S1470-2045(13)70381-4. Epub 2013 Sep 11.

PMID:
24035405
18.

Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.

van den Bogaert DP, Pouw EM, van Wijhe G, Vernhout RM, Surmont VF, Hoogsteden HC, van Klaveren RJ.

J Thorac Oncol. 2006 Jan;1(1):25-30.

19.

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.

van Haarst JM, Baas P, Manegold Ch, Schouwink JH, Burgers JA, de Bruin HG, Mooi WJ, van Klaveren RJ, de Jonge MJ, van Meerbeeck JP.

Br J Cancer. 2002 Feb 1;86(3):342-5.

20.

Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.

Azzoli CG, Patel JD, Krug LM, Miller V, James L, Kris MG, Ginsberg M, Subzwari S, Tyson L, Dunne M, May J, Huntington M, Saunders M, Sirotnak FM.

J Thorac Oncol. 2011 Nov;6(11):1915-22. doi: 10.1097/JTO.0b013e31822adb19.

Supplemental Content

Support Center